Affinium Pharmaceuticals Closes US$18 Million Series A to Advance Clinical Development of Novel Antibacterial Compound
Published: Mar 26, 2007
TORONTO--(BUSINESS WIRE)--Affinium Pharmaceuticals, Inc., a privately held developer of a novel class of oral antibacterial therapeutics, announces the closing of its US$18 million Series A financing. Affinium will use the proceeds from the financing to fund development of its lead candidate through Phase 2 clinical trials. The international financing was led by Forward Ventures and includes new investors Oxford Bioscience Partners, SV Life Sciences, and existing investor Genesys Capital Partners.